Design Therapeutics, Inc.
DSGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $596 | $537 | $466 | $0 |
| Gross Profit | -$596 | -$537 | -$466 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $44,350 | $57,063 | $48,613 | $24,778 |
| G&A Expenses | $18,033 | $21,127 | $18,980 | $11,053 |
| SG&A Expenses | $18,033 | $21,127 | $18,980 | $11,053 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$596 | -$537 | -$466 | $0 |
| Operating Expenses | $61,787 | $77,653 | $67,127 | $35,831 |
| Operating Income | -$62,383 | -$78,190 | -$67,593 | -$35,831 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $12,795 | $11,328 | $4,285 | $298 |
| Pre-Tax Income | -$49,588 | -$66,862 | -$63,308 | -$35,533 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$49,588 | -$66,862 | -$63,308 | -$35,533 |
| % Margin | – | – | – | – |
| EPS | -0.88 | -1.19 | -1.14 | -0.77 |
| % Growth | 26.1% | -4.4% | -48.1% | – |
| EPS Diluted | -0.88 | -1.19 | -1.14 | -0.77 |
| Weighted Avg Shares Out | 56,587 | 55,985 | 55,708 | 45,940 |
| Weighted Avg Shares Out Dil | 56,587 | 55,985 | 55,708 | 45,940 |
| Supplemental Information | – | – | – | – |
| Interest Income | $12,795 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $596 | $537 | $466 | $129 |
| EBITDA | -$48,992 | -$66,325 | -$62,842 | -$35,702 |
| % Margin | – | – | – | – |